Dr. Vitek’s group develops statistical methods and software for quantitative mass spectrometry-based investigations, to characterize the components of the biological systems, their function, and their relevance to disease.

The unique offerings at BATL meet the needs of multiple and diverse scientific and medical stakeholders, from early discovery and development in industry to experiential training, from global regulatory convergence to use-inspired research.

Research in Dr. Beuning’s group focuses on understanding the structure-function-dynamics relationships of proteins and enzymes, with a particular focus on proteins involved in DNA metabolism and DNA damage tolerance.

Dr. Giese’s research focuses on testing biosamples such as breath, placenta and urine for small molecules by mass tag mass spectrometry, including metabolome and DNA adductome analyses.

Dr. Gyori’s research focuses on the intersection of systems biology, bioinformatics, and artificial intelligence to understand how biological cells work and react to drugs and environmental signals.

Dr. Ivanov’s group develops microscale liquid phase separation- and mass spectrometry-based molecular characterization technologies for deep proteomic profiling of limited biological and clinical samples; detailed analysis of proteins, including isoforms, modifications, and non-covalent complexes; and isolation and omics profiling of exosomes and other extracellular microvesicles.

Dr. Jin’s research aims to use geometric and generative AI models to improve the costly, time-consuming process of drug discovery.

Dr. Skinner’s group uses mass spectrometry-based metabolomics and native proteomics to determine how metabolites and proteins interact in human health and disease.

Dr. Slavov’s group develops methods for quantifying proteins in single cells at high-throughput. They apply these methods to analyze protein networks at single-cell resolution and link the network states to functional phenotypes, such as cell type and differentiation potentials.

Dr. Tian’s group develops and applies chromatography-mass spectrometry methods to analyze emerging organic contaminants in environmental and biological samples, assessing the risks to human health and the ecosystem.

Research in Dr. Zhou’s laboratory, aka SunnyLand, centers on the chemistry and analysis of proteins, including hybrid modality engineering, developing new methodologies and creating better therapeutics.

Dr. Deravi’s group works at the interface of bio-analytical chemistry, materials science, and design, where they investigate fundamental mechanisms behind systems in biology and design new classes of protein-based biomaterials that may interface with or enhance the performance of humans.

Dr. Radivojac’s group studies protein structure, dynamics, expression, and function by integrating various forms of molecular and genetic data and develop machine learning approaches to make predictions. Understanding protein function is a step towards understanding molecular mechanisms of human genetic disease.

Dr. Karger is the founding director of the Barnett Institute.